Shots:

• The Carolyn Trial of the EnGeneIC Dream Vector (EDV) nanocell treatment demonstrated a significant increase in OS, with 88% of participants doubling historical rates. The longest-surviving patient lived for an unprecedented 19.7mos. while 8/17 patients survived over 6mos. vs <2mos. historically
• To combat drug resistance in PDAC patients, EDV – ANDC was combined with a potent cytotoxic drug. Despite this, minimal to no toxicity was observed, resulting in significantly improved patient well-being compared to previous CT regimens
• Over 80% of EDV-treated patients maintained or gained weight, in contrast to the typical severe weight loss in advanced PDAC. This provides hope for enhanced quality of life alongside effective treatment. The above results were published in “Clinical Cancer Research”

Ref: Globe Newswire | Image: EnGene

Related News:- Jacobio Pharma’s Glecirasib Receives the NMPA’s Breakthrough Therapy Designation for the Treatment of Pancreatic Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com